Contact Person : Karen
Phone Number : 13892020662
WhatsApp : +8613892020662
September 18, 2021
This treatment applies to the following species:
For oral use in dogs and cats only
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Federal law prohibits the extralabel use of this drug in food-producing animals. |
Marbofloxacin is a synthetic broad-spectrum antibacterial agent from the fluoroquinolone class of chemotherapeutic agents. Marbofloxacin is the non-proprietary designation for 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2] benzoxadiazine-6-carboxylic acid. The empirical formula is C17H19FN4O4 and the molecular weight is 362.36. The compound is soluble in water; however, solubility decreases in alkaline conditions. The N-octanol/water partition coefficient (Kow) is 0.835 measured at pH 7 and 25°C.
Figure 1: Chemical structure of marbofloxacin
In vitro plasma protein binding of marbofloxacin in dogs was 9.1% and in cats was 7.3%. In the cat, approximately 70% of an oral dose is excreted in the urine as marbofloxacin and metabolites with approximately 85% of the excreted material as unchanged drug. Pharmacokinetic parameters related to intravenous dosing were estimated in a study of 6 healthy adult beagle dogs, and are summarized in Table 1. The absolute bioavailability following dosing of oral tablets to the same animals was 94%.
Marbofloxacin plasma concentrations were determined over time in healthy adult beagle dogs (6 dogs per dosage group) following single oral doses of 1.25 mg/lb or 2.5 mg/lb. Absorption of orally administered marbofloxacin increases proportionally over the dose range of 1.25 to 2.5 mg/lb. Marbofloxacin plasma concentrations were determined over time in 7 healthy adult male cats following a single oral dose of 2.5 mg/lb. Plasma pharmacokinetic parameters following oral dosing of dogs and cats are summarized in Figures 2 and 3 and in Table 2. Based on the terminal elimination half-life and the dosing interval, steady-state levels are reached after the third dose and are expected to be approximately 25% greater in dogs and 35% greater in cats than those achieved after a single dose. Marbofloxacin is widely distributed in canine tissues. Tissue concentrations of marbofloxacin were determined in healthy male beagle dogs (4 dogs per time period) at 2, 18 and 24 hours after a single oral dose (1.25 or 2.5 mg/lb) and are summarized in Tables 3a and 3b.
Table 1: Mean pharmacokinetic parameters following intravenous administration of marbofloxacin to 6 adult beagle dogs at a dosage of 2.5 mg/lb. | |
Parameter |
Estimate ± SD* n=6 |
Total body clearance, (mL/h•kg) | 94 ± 8 |
Volume of distribution at steady state, VSS, (L/kg) | 1.19 ± 0.08 |
AUC0-inf (µg•h/mL) | 59 ± 5 |
Terminal plasma elimination half-life, t1/2(h) | 9.5 ± 0.7 |
* SD = standard deviation |
Table 2: Mean pharmacokinetic parameters following oral administration of marbofloxacin tablets to adult beagle dogs at a nominal dosage of 1.25 mg/lb or 2.5 mg/lb and to cats at 2.5 mg/lb. | |||
Parameter |
Dog Estimate ± SD* (1.25 mg/lb) n=6 |
Dog Estimate ± SD* (2.5 mg/lb) n=6 |
Cat Estimate ± SD* (2.5 mg/lb) n=7 |
Time of maximum concentration, Tmax (h) | 1.5 ± 0.3 | 1.8 ± 0.3 | 1.2 ± 0.6 |
Maximum concentration, Cmax, (µg/mL) | 2.0 ± 0.2 | 4.2 ± 0.5 | 4.8 ± 0.7 |
AUC0-inf (µg•h/mL) | 31.2 ± 1.6 | 64 ± 8 | 70 ± 6 |
Terminal plasma elimination half-life, t1/2(h) | 10.7 ± 1.6 | 10.9 ± 0.6 | 12.7 ± 1.1 |
mean actual dosages administered to dogs were 1.22 mg/lb and 2.56 mg/lb, respectively, and the mean actual dosage administered to cats was 2.82 mg/lb. * SD = standard deviation |
Figure 2: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult beagle dogs at dosages of 1.25 mg/lb or 2.5 mg/lb.
* See Table 4 in Microbiology section for MIC data.
Figure 3: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult cats at a dosage of 2.5 mg/lb.
* See Table 5 in Microbiology section for MIC data.
Table 3a: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 1.25 mg/lb. | |||
Marbofloxacin Concentrations (µg/g ± SD*) |
|||
Tissue |
2 hours (n=4) |
18 hours (n=4) |
24 hours (n=4) |
bladder | 4.8 ± 1.1 | 2.6 ± 1.5 | 1.11 ± 0.19 |
bone marrow | 3.1 ± 0.5 | 1.5 ± 1.5 | 0.7 ± 0.2 |
feces | 15 ± 9 | 48 ± 40 | 26 ± 11 |
jejunum | 3.6 ± 0.5 | 1.3 ± 1.0 | 0.7 ± 0.3 |
kidney | 7.1 ± 1.7 | 1.4 ± 0.5 | 0.9 ± 0.3 |
lung | 3.0 ± 0.5 | 0.8 ± 0.2 | 0.57 ± 0.19 |
lymph node | 5.5 ± 1.1 | 1.3 ± 0.3 | 1.0 ± 0.3 |
muscle | 4.1 ± 0.3 | 1.0 ± 0.3 | 0.7 ± 0.2 |
prostate | 5.6 ± 1.4 | 1.8 ± 0.6 | 1.1 ± 0.4 |
skin | 1.9 ± 0.6 | 0.41 ± 0.13 | 0.32 ± 0.08 |
* SD = standard deviation |
Table 3b: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 2.5 mg/lb. | |||
Marbofloxacin Concentrations (µg/g ± SD*) | |||
Tissue |
2 hours (n=4) |
18 hours (n=4) |
24 hours (n=4) |
bladder | 12 ± 4 | 6 ± 7 | 1.8 ± 0.4 |
bone marrow | 4.6 ± 1.5 | 1.28 ± 0.13 | 0.9 ± 0.3 |
feces | 18 ± 3 | 52 ± 17 | 47 ± 28 |
jejunum | 7.8 ± 1.1 | 2.0 ± 0.3 | 1.1 ± 0.3 |
kidney | 12.7 ± 1.7 | 2.7 ± 0.3 | 1.6 ± 0.2 |
lung | 5.48 ± 0.17 | 1.45 ± 0.19 | 1.0 ± 0.2 |
lymph node | 8.3 ± 0.7 | 2.3 ± 0.5 | 2.03 ± 0.06 |
muscle | 7.5 ± 0.5 | 1.8 ± 0.3 | 1.20 ± 0.12 |
prostate | 11 ± 3 | 2.7 ± 1.0 | 2.0 ± 0.5 |
skin | 3.20 ± 0.33 | 0.705 ± 0.013 | 0.46 ± 0.09 |
* SD = standard deviation |
Microbiology: The primary action of fluoroquinolones is to inhibit the bacterial enzyme, DNA gyrase. In susceptible organisms, fluoroquinolones are rapidly bactericidal at relatively low concentrations. Marbofloxacin is bactericidal against a broad range of gram-negative and gram-positive organisms. The minimum inhibitory concentrations (MICs) of pathogens isolated in clinical field studies performed in the United States were determined using National Committee for Clinical Laboratory Standards (NCCLS) standards, and are shown in Tables 4 and 5.
Table 4: MIC Values* (μg/mL) of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs enrolled in clinical studies conducted during 1994-1996. | ||||
Organism | No. of Isolates | MIC50 | MIC90 | MIC Range |
Staphylococcus intermedius | 135 | 0.25 | 0.25 | 0.125 - 2 |
Escherichia coli | 61 | 0.03 | 0.06 | 0.015 - 2 |
Proteus mirabilis | 35 | 0.06 | 0.125 | 0.03 - 0.25 |
Beta-hemolytic Streptococcus, (not Group A or Group B) | 25 | 1 | 2 | 0.5 - 16 |
Streptococcus, Group D enterococcus | 16 | 1 | 4 | 0.008 - 4 |
Pasteurella multocida | 13 | 0.015 | 0.06 | ≤0.008 - 0.5 |
Staphylococcus aureus | 12 | 0.25 | 0.25 | 0.25 - 0.5 |
Enterococcus faecalis | 11 | 2 | 2 | 1 - 4 |
Klebsiella pneumoniae | 11 | 0.06 | 0.06 | 0.01 - 0.06 |
Pseudomonas spp. | 9 | ** | ** | 0.06 - 1 |
Pseudomonas aeruginosa | 7 | ** | ** | 0.25 - 1 |
Get in touch with us
Enter Your Message |